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humans remains largely unknown. Studies in animals have been especially unreliable in predicting human teratogenicity, and examples of false-positive and false-negative predictions based on these studies are well known [7] . The difficulty of separating the potential adverse effects of a drug from the underlying disease process for which the drug was administered further complicates the issue and often renders it impossible to draw valid conclusions regarding drug toxicity [8] . On the other hand, condemnation of useful agents on the basis of unproven risks, particularly when therapy is clearly required, is unjustified and disconcerting. Clearly, more effective collection of data and carefully controlled, prospective, epidemiologic and statistical investigations of drug safety during human pregnancy are urgently needed.
In this review, which is intended only as a guide, we shall consider the commonly employed antimicrobial agents and their use during pregnancy. Our hope is that the proven and theoretic effects of the antepartum use of these agents on both maternal and fetal outcome will be more readily recognized and that more precise therapeutic indications will be developed. 
Antimicrobial Use During Pregnancy and Puerperium

Pharmacokinetic Factors
The dynamic interactions of drug absorption, distribution, receptor activity, metabolism, and elimination are closely linked in at least three major functional compartments: those of the mother, the placenta, and the fetus (figure 1). When the pharmacokinetic properties of antimicrobial agents during pregnancy are considered, a number of technical problems and limitations become apparent.
First, meaningful information can be obtained only on agents whose levels can be accurately assayed and (if metabolized) whose metabolites can be readily measured. Second, for studies of antibiotics in maternal or fetal plasma or serum, standards should preferably be prepared in corresponding plasma or serum from age-matched, untreated pregnant women or fetuses. This requirement is particularly important since drugs may bind differently in fetal and adult plasma and at different stages of gestation [9, 10]. For example, as levels of antibiotics in plasma or serum are determined in microbiologic assays for the free or unbound fractions, samples from a fetus with a low degree of protein binding will give falsely high values if compared with standards with a higher degree of protein binding, and vice versa. Ideally, for valid comparisons of antibiotic pharmacokinetics in the pregnant and nonpregnant states, control samples should be obtained from the same women before and after pregnancy [10] . This approach would eliminate the influences of variations in those pharmacokinetic parameters that are primarily genetically determined. If such an approach is not possible, appropriate control samples from nonpregnant women should at least be matched for age, weight, and (if possible) underlying medical conditions. Third, various pharmaceutical compounds are often administered concomitantly during labor or surgery, and the possible influence of these agents on the pharmacokinetics of an antibiotic may be difficult to evaluate. Fourth, the technical as well as ethical problems related to sampling and pharmacokinetic studies of fetal tissue (such as freeing tissue from blood and extracting the antibiotic) are numerous and immense. These limitations must be carefully considered if such data are to be interpreted critically and meaningfully.
Finally, the fate of antimicrobial metabolites and the relation of these metabolites to toxicity in the pregnant woman and the fetus remain largely unexplored. Even though a metabolite may be microbiologically inactive and therefore may not be measured by bioassay techniques, it may still possess toxic potential. This possibility should be systematically examined by modern antimicrobial assay techniques (such as high-pressure liquid chromatography) that allow simultaneous quantitation of biologically inactive and biologically active metabolites.
Maternalphysiologic considerations. During pregnancy a number of physiologic changes in the mother may modify the pharmacokinetics of therapeutic agents. Important among these are maternal adaptations that serve to increase the delivery of blood and nutrients to the fetus and to remove metabolic waste products from both mother and fetus [11-13]. These adaptations generally result in a marked increase in both the intravascular and extravascular volumes; the enhancement of cardiac output, renal blood flow, and the glomerular filtration rate; and the augmentation of hepatic and other metabolic activities in the mother, the fetus, and the placenta [14] . Consequently, the volume of distribution-as well as the metabolic degradation and renal clearance of the administered drug-can alter significantly in comparison with corresponding values obtained in the nonpregnant state. Furthermore, the plasma albumin concentration decreases from a mean of 4.3 g/dl in the nonpregnant state to a mean of 3.0 g/dl in late pregnancy [15] . This modification may directly affect the ratio of bound to free fractions of many antimicrobial agents and may ultimately result in a lower total serum level of the drug, an increase in the tissue-to-plasma distribution ratio, and an increase in the rate of drug clearance from the body.
Both the tone and the motility of the maternal gastrointestinal tract may be reduced as a consequence of physical displacement by the enlarging uterus; these changes may result in delayed gastric emptying and prolonged intestinal transit [13] . The latter effects may in turn influence either the bioavailability and effectiveness of drugs with acid-labile properties or the site-specific absorption of drugs from the intestinal tract [11, 12] . Finally, progressive thinning of the fetomaternal "barrier" as gestation advances results in increased transplacental diffusion and alternative routes of drug elimination from the mother [14, 16]. These pregnancy-associated physiologic changes and their therapeutic implications are summarized in table 1. The net influence of these physiologic changes of pregnancy is that maternal The maternal adaptive changes most likely to influence drug pharmacokinetics are most evident in the third trimester of pregnancy and immediately postpartum; the degree of change varies considerably from individual to individual. Precise data on the time course of the return of these various physiologic adaptations toward normal during the puerperium are lacking. It is known that in the immediate postpartum period the pattern of maternal disposition of drugs remains similar to that during late pregnancy despite the removal of pharmacokinetic influences from the placenta and the fetus. Thus, the therapeutic implications of altered pharmacokinetic properties of antimicrobial agents should still be considered in the postpartum period.
Placental transfer and excretion in amniotic fluid. Movement of compounds across the placenta is generally bidirectional, although the net transfer occurs from mother to fetus in most instances. The transplacental passage of an antimicrobial agent is regulated by many factors, principally the physiologic characteristics of the maternal-placental-fetal unit and the physicochemical properties of the drug [23]. Physiologic factors include (1) hemodynamic changes in either the maternal or the fetal contribution to total placental blood flow, (2) the thickness and maturation of the placental membranes, and (3) the metabolic activity of placental tissues.
Although active and facilitated transport of some substances across the placenta has been demonstrated [6], the transplacental passage of antimicrobial agents occurs primarily by simple diffusion. It follows, therefore, that almost all drugs taken by a pregnant woman can cross the placenta to some degree. The rate-limiting factors in the placental transfer of antibiotics are identical to those that govern membrane diffusion by molecules. Thus, the rate of diffusion across the placental barrier is directly proportional to the maternal-fetal concentration gradient and the surface area of the placenta and is inversely proportional to the thickness of the placental membrane [23, 24]. Early in pregnancy the placental membrane is relatively thick, and this characteristic tends to reduce permeability. The thickness of the trophoblastic epithelium decreases in the last trimester (i.e., from 25 im early in gestation to 2 tm at birth [23]), and any passage of drugs is thereby greatly facilitated [6, 28]. Various disease states, including diabetes and toxemia of pregnancy, significantly alter the permeability characteristics of the placental membrane [6] . A drug with a molecular weight of <500, a high degree of lipid solubility, a low degree of ionization, and a low affinity for protein binding thus is able to traverse the placenta more readily. A drug with a molecular weight of >1,000 may be restricted by its size. Only the unbound (free) fraction of a drug is subject to placental transfer; therefore, the more a drug is bound to maternal plasma proteins, the less it is available for crossing to the fetus [23].
Although some variations exist in the placental transfer of many antibiotics (such as ampicillin, cephalothin, clindamycin, carbenicillin, and the aminoglycosides), most follow a similar pattern [16] . After a single intravenous infusion into the mother, antibiotic concentrations usually peak in umbilical blood within 30-60 min of the time they peak in maternal serum. Fetal-to-maternal peak serum level ratios have ranged between 0.3 and 0.9 for ampicillin, cephalothin, clindamycin, carbenicillin, and the aminoglycosides, while those for erythromycin and dicloxacillin are more limited ((0.1) [11, 16]. The relative concentrations of ampicillin, methicillin, and dicloxacillin in the fetal and maternal circulation are related to the respective capacity of these drugs for protein binding [11] . Ampicillin, which is least protein bound (20%), reaches high levels in the fetus and in amniotic fluid; in contrast, methicillin (40% bound) and dicloxacillin (96% bound) achieve higher maternal levels but progressively lower levels in the fetus and amniotic fluid. On this basis dicloxacillin may be suitable for treatment of a maternal infection but may not be useful for an intrauterine infection.
A considerable time lag in antibiotic penetration of the amniotic fluid is noted after intravenous infusion into the mother. This delay, which may be several hours in length, apparently is attributable to the fact that antibiotic levels in amniotic fluid during the third trimester are to a great extent dependent on antibiotic excretion in fetal urine [ The lipid solubility, ionization, and protein-binding characteristics of antimicrobial agents are important determinants of drug distribution in various fetal compartments and selective tissue uptake. Levels of highly protein-bound antibiotics tend to be considerably lower in fetal serum than in maternal serum; in contrast, fetal levels of antibiotics that are poorly protein bound approach maternal levels. Occasionally, drugs such as sulfisoxazole, which is more extensively bound in umbilical serum than in maternal serum may reach therapeutic concentrations in fetal serum despite a relatively high proteinbinding characteristic [ . This syndrome appears to be specific to pregnant women who have reduced renal function. Although isoniazid also appears to possess greater potential for hepatotoxicity in pregnant than in nonpregnant women, treatment of active tuberculosis should not be deferred [61, 63] . Some investigators have recommended that if a woman has a positive tuberculin skin-test result or is exposed to tuberculosis during pregnancy (as indicated by recent tuberculin skintest conversion), she need not be given isoniazid until after the pregnancy is terminated [67] . Others, however, have suggested that chemoprophylaxis with isoniazid may be given in late pregnancy, especially in areas with a high endemic incidence of active tuberculosis [68] . For reasons that are not entirely clear, the risk of active tuberculosis is greater during the postpartum period than during pregnancy [67] .
(2) Therapeutic efficacy. Apart from drug safety and tolerability, pharmacokinetic characteristics and the site and nature of infection are critical factors that determine therapeutic options and ultimate outcome. For certain infections (e.g., those of the urinary tract), the decrease in serum antibiotic concentrations attained during pregnancy may be of little consequence, particularly if the site of infection is also the site of drug excretion and local drug concentrations are adequate to produce the desired therapeutic effect. In infections requiring high serum concentrations for therapeutic efficacy (e.g., infective endocarditis), much higher dosage schedules may be required than those recommended for nonpregnant patients. Such instances require close monitoring of serum drug levels to assure adequate dosage and to avoid toxicity to the mother or the fetus [1] .
Finally, the treatment of infections affecting both the mother and the fetus requires special attention. In these cases the optimal antimicrobial agent not only should cure the infection promptly in the mother but also should be capable of readily crossing the placenta and achieving bactericidal levels in fetal tissues. Such an agent must be devoid of known teratogenic effects, have a wide margin of safety, and possess the capability to cure fetal infection at any stage of gestation [1] . In the treatment of syphilis, penicillin comes closest to meeting these ideal criteria [69] . In the treatment of chorioamnionitis, however, despite excellent maternal and fetal serum concentrations, ampicillin may be unsatisfactory because peak levels in amniotic fluid remain inadequate until 4-6 hr after initiation of therapy [17]. In addition, the fetal lung inoculated by infected amniotic fluid would have suboptimal antibiotic concentrations because blood is shunted away from the lung by the fetal circulation. Therefore, antimicrobial treatment of chorioamnionitis accompanied by intrauterine pneumonia is frequently suboptimal, and early delivery of the fetus is recommended [14].
Fetal considerations. (1) Adverse effects. The effects of exposure of the fetus to drugs seldom comprise an all-or-none phenomenon; only rarely do specific agents produce specific birth defects. There are five principal periods of concern with regard to the use of antimicrobial agents during pregnancy; (1) the preconception or preimplantation period; (2) the postimplantation or organogenesis period (first trimester); (3) the fetal development period (second and third trimesters); (4) the labor and delivery period; and (5) the puerperium and breast-feeding period [7] . Animal studies suggest that drug treatment of either parent before conception may result in abnormal embryonic development or intrauterine death [32] . During the first week after conception, prior to the actual implantation of the fertilized ovum within the uterus, potential teratogens probably do exert an all-or-none effect; i.e., either the embryo dies or its damaged cells are replaced by undifferentiated cells that develop in an entirely normal fashion. Differentiation of the embryo begins at two weeks, and it is during this period that most major morphologic congenital abnormalities may be produced [7, 70] . Drug exposure during the fetal development period in the second and third trimesters is associated with a much lower risk of major birth defects, since at this stage most major organ systems are already well developed and are much less susceptible to teratogenic effects [6, 7, 70, 71]. Although the overall incidence of major congenital malformations is rv2%-3%o and minor defects may be evident in as many as 9% of newborns [70] , the contribution of drug exposure to this problem is probably very small. It is estimated that only 10%7 of congenital malformations are attributable to environmental causes, including drugs, while 25% are due to genetic or chromosomal abnormalities. Fully 65% of all reported congenital defects have no known identifiable cause [70] .
The mechanisms by which a drug exerts a teratogenic effect are still poorly understood. Antimicrobial agents may influence fetal development indirectly by their effects on maternal tissues, which include a reduction of the oxygen-carrying capacity of blood, the induction of hypo-or hyperglycemia, a diminution of vitamin availability, or alterations in the supply of hormones, amino acids, and trace elements [7, 72] . These agents may also exert a direct embryotoxic effect in the intrauterine environment. Alternatively, antimicrobial agents may adversely affect the placenta by interfering with the normal passage of oxygen, glucose, or other nutrients [72] . The placenta is an organ of major metabolic significance since it is capable of oxidation, reduction, conjugation, and hydroxylation reactions [6, 71]. Changes in placental function are expected to influence adversely the disposition of many drugs and the subsequent development of the fetus [72] .
(2) Therapeutic efficacy. Although many antimicrobial agents cross the placenta and reach measurable concentrations in umbilical serum or amniotic fluid, the administration of antibiotics to the pregnant mother may not be the best way to treat a fetal Endometritis may become established during labor or immediately in the postpartum period [74] . The incidence of infection is 1%-4% after normal labor [75] . Infection is most common after assisted delivery or trauma, especially after emergency cesarean section. There is usually a mild fever associated with uterine tenderness and foul-smelling lochia. Serious septicemia and pelvic peritonitis develop occasionally. Initial antibacterial therapy should be with ampicillin or a cephalosporin. If retained placental tissue is suspected or persistent bleeding is noted, the uterine cavity must be explored and emptied once parenteral antimicrobial therapy has been administered for at least 6 hr [74] .
(6) Premature rupture of membranes and primary cesarean section. Since the rate of postpartum fe- Women with congenital heart disease (other than uncomplicated ostium secundum atrial-septal defects), rheumatic valvular heart disease, and acquired valvular heart disease should be considered candidates for prophylaxis prior to these procedures. In cases of mitral valve prolapse, only women with a mitral regurgitation murmur (and not those with isolated clicks) require prophylaxis for infective endocarditis [77] .
Specific Antimicrobial Agents in Pregnancy
Current information on the pharmacokinetic and toxicologic characteristics of many antimicrobial agents during pregnancy is summarized in table 4. Serum levels of chloramphenicol in pregnant women are comparable to those in nonpregnant individuals [104] . Transplacental passage of the drug occurs readily, with fetal serum concentrations reaching 30%-150% of simultaneous maternal levels [104] . Although chloramphenicol is secreted in breast milk, the quantities are insufficient to induce Gray syndrome.
Metronidazole. Metronidazole readily crosses the placenta [42]. Serum levels of this drug during pregnancy are comparable to those in nonpregnant women, and fetal serum concentrations approach maternal levels [42] . Although metronidazole has been found to be carcinogenic in rodents and mutagenic for certain bacteria [107, 147] , there is no firm evidence for teratogenicity or an increased rate of congenital birth defects after administration to pregnant women [55] [56] [57] [58] . Nevertheless, most obstetricians refrain from using this drug during the first trimester and, when possible, during the last trimester and breast-feeding. Metronidazole may cause a number of adverse reactions in pregnant women, including convulsions, peripheral neuropathy, reversible neutropenia, and intolerance to alcohol [107] . However, these reactions would not be expected to occur more often than in nonpregnant patients. Nitrofurantoin, nalidixic acid, and methenamine salts. Serum levels of nitrofurantoin have been reported to decrease during pregnancy [9, 10]. This agent has also been shown to cross the placenta and achieve a high fetal-maternal serum concentration ratio [52] . Although the placenta is readily breached, therapeutic levels are not maintained in cord serum, probably because of rapid renal excretion. Nitrofurantoin does not appear to reach significant concentrations in the amniotic fluid, and its excretion in breast milk is clinically insignificant [59] . This drug is frequently chosen for the treatment of urinary tract infections in women during pregnancy; it appears to be safe for both the mother and the fetus [53] . There is a theoretic risk of hemolysis in the fetus and neonate, with relative G6PD deficiency [114] . Nalidixic acid crosses the placenta. It is highly protein bound and is excreted in both amniotic fluid and breast milk [115, 116] . The incidence of adverse reactions to nalidixic acid is low, although the drug occasionally causes toxic psychosis and convulsions and should be avoided in patients with seizure disorders. This agent has been reported to cause increased intracranial pressure, papilledema, and bulging fontanelles in the newborn infant [148] . Nalidixic acid should be used with caution during pregnancy and avoided altogether during the first trimester; its use is not recommended in nursing mothers and infants under three months of age.
Methenamine mandelate is absorbed rapidly following oral administration. Its distribution in maternal and fetal tissues and in amniotic fluid has not been well studied. Nevertheless, it appears to be safe during pregnancy and can be used as a urinary antiseptic for the treatment of bacteriuria [149] . Although ototoxicity related to short-term therapy is infrequent, aminoglycosides should be avoided if at all possible during pregnancy. In situations where use of aminoglycosides is indicated because of severe infection and lack of suitable alternatives, caution should be exercised, especially if preterm delivery is anticipated. Careful monitoring of maternal serum levels throughout therapy is strongly recommended not only to minimize fetal exposure to excessive drug levels but also to ensure the optimal outcome of treatment through the avoidance of subtherapeutic levels in the mother.
Spectinomycin. Spectinomycin is an aminocyclitol antibiotic structurally and biochemically different from the aminoglycosides. It is currently used exclusively for the treatment of gonorrhea [123] . The drug is rapidly absorbed after intramuscular injection and is weakly protein bound. The penetration of spectinomycin into fetal tissues, amniotic fluid, or breast milk has not been adequately studied. Unlike the aminoglycosides, spectinomycin does not appear to be toxic in terms of cochlear, vestibular, or renal function. Available data do not suggest that spectinomycin is teratogenic or poses unique risks to either mother or fetus [123] . It is presently the drug of choice in pregnant women with uncomplicated gonorrhea who are allergic to penicillin or whose infection is caused by penicillinase-producing strains of Neisseria gonorrhoeae [69, 123] .
Vancomycin. Vancomycin is glycopolypeptide antibiotic useful for the treatment of a variety of serious infections, including endocarditis, shuntassociated or prosthetic infections, staphylococcal enterocolitis, and antibiotic-associated pseudomembranous colitis [125] . Although unrelated to the aminoglycosides, vancomycin can also cause ototoxicity and nephrotoxicity. Studies in animals, including pregnant rabbits and cats, indicate that vancomycin crosses the placenta and penetrates into fetal serum, amniotic fluid, and breast milk [126] . Data from studies in humans, however, are lacking. The use of vancomycin during pregnancy should be restricted to cases of life-threatening infections for which no alternative antibiotics are available.
Antituberculous Drugs
Since the outcome of pregnancy among women receiving antituberculous therapy with the first-line agents (including isoniazid, ethambutol, and rifampin) does not differ significantly from that among the general population, the use of these agents during pregnancy is not contraindicated [61, 63] . Isoniazid appears to be the safest and most effective of the available antituberculous agents and is relatively well tolerated during pregnancy. It readily crosses the placenta and is excreted in breast milk [16, 59, 61]. Isoniazid is potentially hepatotoxic; it has been suggested that this risk is increased in rapid acetylators (e.g., Orientals and Eskimos) and in pregnant women [67] . For this reason, unless active infection is present, some authors have recommended that isoniazid prophylaxis for recent tuberculin skin-test conversion be delayed until after delivery [67] . However, other authorities have suggested that such treatment may be given in late pregnancy, especially in areas with a high endemic incidence of active tuberculosis [68] .
Ethambutol has also been used extensively dur- The increased risk of ototoxicity in infants of mothers who receive prolonged courses of streptomycin during pregnancy has been previously discussed (see section on aminoglycosides). Streptomycin is no longer considered a first-line antituberculous agent.
Antifungal Drugs
Little has been documented about the use of systemic antifungal drugs during pregnancy. Ismail and Lerner [130] recently reviewed the published experience with amphotericin B among 21 pregnant women. The adverse effects of amphotericin B, such as nephrotoxicity with azotemia and hypokalemia, seem to be no worse in pregnant than in nonpregnant patients. No increase in the incidence of teratogenesis or of persistent toxic effects on the fetus or the neonate was found. Amphotericin B crosses the placenta and reaches concentrations in fetal serum that are approximately one-third as high as those in maternal serum [130] ; fetal serum levels may approach maternal levels near delivery [131] . Inadequate data exist regarding the penetration of this agent into amniotic fluid [130] .
Flucytosine is teratogenic in rats [132, 133] and for this reason is contraindicated during pregnancy. This agent is water soluble and is absorbed intact from the gastrointestinal tract. Its binding to plasma proteins is negligible, and it penetrates tissues well [133] .
Among the antifungal imidazoles, only miconazole and ketoconazole appear to be useful against systemic mycoses. Miconazole has thus far failed to play a major role in antifungal chemotherapy, primarily because of its toxicity [134] . Its safety during pregnancy has not been established. When used topically, miconazole is absorbed from the vagina in trace amounts, and the benefits of its use in pregnancy should be carefully weighed against the potential risks [135, 136] . Ketoconazole is the first of the antifungal imidazoles to be well absorbed orally. It is effective against infections caused by diverse fungi (including dermatophytes) and against mucocutaneous candidiasis and deep mycosis [134] . The pharmacokinetic properties of ketoconazole are incompletely defined. The drug is highly protein bound and extensively metabolized. It has surprisingly few adverse effects when administered orally, although both hepatitis and adrenal suppression have been reported [137] . The degree to which ketoconazole is absorbed by fetal tissues and amniotic fluid is unknown, and its safety in pregnancy has not been established.
Griseofulvin is an antimicrobial agent with limited fungicidal activity that is used primarily for the treatment of dermatophytic infections of the scalp and nails. It is inconsistently absorbed from the gastrointestinal tract and is extensively metabolized in the liver. Griseofulvin crosses the placenta poorly and is not detected in amniotic fluid [138] . It has been found to be embryotoxic and teratogenic when administered to pregnant mice [139] and is not recommended for use in human pregnancy.
Antiviral Drugs
In contrast to the remarkable progress made in the treatment of bacterial infections in the past four decades, only a few major advances in antiviral chemotherapy have developed. These few include the use of amantadine and its derivatives for the prophylaxis and treatment of influenza, the use of vidarabine and acyclovir for the treatment of lifethreatening herpes simplex and varicella-zoster infections, and the use of acyclovir for the treatment of genital herpes simplex infection [140] . Idoxuridine and cytarabine are too toxic for systemic use and are reserved primarily for topical treatment of herpes keratitis.
Amantadine is absorbed rapidly and completely after oral administration. It is not metabolized in humans, and 90% of the administered dose is excreted unchanged in the urine. The drug is also excreted in milk, but its other pharmacokinetic properties during pregnancy in humans are unknown. Because amantadine in large doses has been found to be embryotoxic and teratogenic for certain laboratory animals, its use in pregnant women should be avoided [140] .
Vidarabine is poorly water soluble, and large volumes of fluids are required for intravenous administration by continuous infusion. This agent is rapidly deaminated to arabinosylhypoxanthine, which also has antiviral activity [140] . Vidarabine is teratogenic in laboratory animals, and its use in pregnant women should be reserved for lifethreatening herpes infections.
Acyclovir is only partially absorbed when administered orally. When infused intravenously, it is widely distributed in tissues and body fluids [142] . Acyclovir is primarily excreted by glomerular filtration and tubular secretion. Extensive studies have failed to demonstrate embryotoxicity or teratogenesis of acyclovir in laboratory animals [143] . Nevertheless, its safety in pregnancy has not yet been established. As a general rule, systemic antiviral agents should be avoided in pregnancy, particularly during the first trimester, except in the presence of life-threatening infections in the mother. Whether treatment with antiviral agents near term is safe for the fetus or can prevent disseminated herpes simplex infection in the newborn remains to be determined.
Antiparasitic Drugs
With the current ease of global travel and the recent influx of immigrants from tropical into nontropical countries, the need to consider the use of various antiparasitic agents during pregnancy has become much more imminent. Unfortunately, reliable data addressing the toxic or teratogenic potential of many of these agents in humans are not available. Furthermore, the natural history and consequences of parasitic infections in both the mother and the fetus are not well understood. In this section only therapy for the more common protozoal and helminthic infections in temperate climates will be considered. The agents of choice for the treatment of some of these infections during pregnancy and the antiparasitic drugs that should specifically be avoided during pregnancy are listed in table 5.
Antiprotozoal drugs. (1) Malaria. Since the contraction of malaria during pregnancy represents a significant risk to the fetus as well as the mother [151] , both treatment and prophylaxis are clearly indicated. Chloroquine is generally safe in pregnant women and poses little teratogenic risk [152] ; thus, it is the drug of choice for chloroquine-sensitive malaria acquired during pregnancy. Chloroquine crosses the placenta and accumulates in fetal ocular tissue [157] ; it produces cochleovestibular damage if administered on a long-term basis in large doses [153, 154] . However, this drug has not been found to have any harmful effect on the fetus when used in the dosages recommended for malaria prophylaxis [152] .
In relapsing malaria due to Plasmodium vivax or Plasmodium ovale, primaquine is recommended along with chloroquine in nonpregnant patients. However, since fetal red blood cells are relatively deficient in G6PD and glutathione, the fetus is at increased risk for intravascular hemolysis and methemoglobinemia [42] . Primaquine, therefore, is not recommended during pregnancy. Pregnant women for whom radical cure or terminal prophylaxis with primaquine is otherwise indicated should receive only chloroquine once weekly until delivery. Primaquine can then be administered after delivery [152] .
Treatment and prophylaxis of choroquineresistant malaria in pregnant women pose a special dilemma, since a number of antimalarial agents effective for this purpose are contraindicated during pregnancy (table 5) . Pyrimethamine, a folic acid antagonist, is teratogenic in laboratory animals, and its safety in human pregnancy has not been established [157] . This drug should be avoided, especially in the first trimester of pregnancy [152] . In addition, the use of long-acting sulfonamides late in pregnancy may be associated with neonatal jaundice and kernicterus. Therefore, women who are pregnant or are likely to become so should not travel to areas where the presence of chloroquineresistant malaria requires prophylaxis with pyrimethamine-sulfadoxine. Pregnant women who cannot avoid exposure to these malarial strains should be informed of the possible risks of fetal teratogenicity and neonatal jaundice before they take Dapsone in combination with pyrimethamine has been useful for the treatment and prophylaxis of chloroquine-resistant falciparum malaria. However, this sulfone induces hemolytic anemia and methemoglobinemia, and several cases of agranulocytosis have been reported in association with its use as an antimalarial agent [156] . Like pyrimethamine-sulfadoxine, pyrimethamine-dapsone is not recommended for use during pregnancy.
Both tetracycline and quinine are contraindicated in pregnancy unless they are required to treat lifethreatening infections in the mother [152] . Quinine in large doses was at one time widely used to induce abortion [70, 157] . Hypoplasia of the optic nerve and congenital deafness have both been reported after failure of attempts to terminate pregnancy [70] . Quinine has also been reported to cause massive intravascular hemolysis followed by acute tubular necrosis and renal failure during pregnancy [155] .
(2) Amebiasis. Experiences in Africa and India suggest that amebiasis may run a more fulminant course and that latent infections may be exacerbated during pregnancy [160] . Treatment of amebiasis during pregnancy is therefore generally warranted. Diiodohydroxyquin, a luminal amebicide, is the agent of choice for asymptomatic infection. Its main adverse effects include iodine hypersensitivity and gastrointestinal upset [163] . Subacute myelo-optic neuropathy has been reported with diiodohydroxyquin, although only when the drug was administered in doses larger than that recommended for amebiasis. This complication is not as frequent with diiodohydroxyquin as with iodochlorhydroxyquin [163] . Diloxanide furoate is an alternative luminal amebicide [163] . Its safety during pregnancy has not been determined, and it should therefore be avoided in this situation [160] .
Symptomatic amebic disease during pregnancy should be treated with metronidazole plus diiodohydroxyquin. The potential teratogenicity and carcinogenicity of metronidazole in rodents has already been discussed. Although there is no firm evidence of teratogenicity in humans, the use of metronidazole in pregnant women should be carefully considered and if possible avoided during the first and last trimesters or during breast-feeding. Both emetine and diloxinide are contraindicated during pregnancy because of potential fetal danger.
(3) Toxoplasmosis. Toxoplasmosis acquired during pregnancy may lead to spontaneous abortion, premature birth, stillbirth, and (most importantly) congenital malformations [158] . The fetus is not affected by maternal infection acquired prior to pregnancy, as it is protected by transplacental passage of maternal antibodies [160] . Furthermore, women giving birth to an affected child are unlikely to have recurrent problems in subsequent pregnancies. Women who acquire the disease during pregnancy, especially during the first five months, should be treated to prevent fetal and congenital complications. In nonpregnant patients pyrimethamine plus sulfadiazine is the preferred combination. Because of possible teratogenic effects of pyrimethamine and potential toxic effects of sulfonamides on the fetus, however, this regimen cannot be advocated during pregnancy [160] . Spiramycin, a macrolide antibiotic similar to erythromycin, is the drug of choice for treatment of toxoplasmosis during pregnancy [159] and is impressive in reducing the overall frequency of fetal infection when administered to the mother [158] . Spiramycin is absorbed incompletely and irregularly when administered orally. It does not cross the placenta freely [158] and is not known to be teratogenic [159] .
(4) Giardiasis. Infection caused by Giardia lamblia is often asymptomatic. Few studies of giardiasis during pregnancy have been reported. Patients with symptomatic infection should be given metronidazole [160] . Quinacrine is not recommended because it crosses the placenta and becomes a potential hazard to the fetus [164] . Furazolidone, a nitrofuran effective in the treatment of giardiasis, is also best avoided during pregnancy since it can cause agranulocytosis and acute hemolysis in individuals with G6PD deficiency [163] . Paromomycin, an aminoglycoside, is not systemically absorbed from the gastrointestinal tract and is a useful alternative agent for treatment of symptomatic giardiasis during pregnancy.
(5) Trichomoniasis. Trichomonas vaginalis is a common protozoan found in the vagina of 10%-25% of all women [160] . This flagellate is identified in ~5%o of infants born of untreated, infected mothers but only rarely causes symptomatic disease [160] . In women with trichomonal vaginitis, metronidazole is highly effective. The low risk of teratogenicity or carcinogenicity in humans suggests that this drug can be administered during pregnancy when therapy is clearly indicated [56, 108] . Treatment of asymptomatic infection, however, is not recommended.
Anthelmintic drugs. (1) Nematodes (roundworms). The rational use of anthelmintic agents during pregnancy requires an understanding of the unique host-parasite relationship. First, in most helminthic infections, human morbidity is directly proportional to worm burden. Second, with rare exception, helminths do not multiply in the human host [165] . Thus, roundworm infestations other than ascariasis and strongyloidiasis are seldom significant during pregnancy, and treatment is usually unwarranted until after delivery. For enterobiasis, trichuriasis, and hookworm infections, the treatment of choice following delivery is mebendazole [165] . This agent has broad-spectrum activity against a variety of nematodes. Although it is poorly absorbed after oral administration, mebendazole is contraindicated during pregnancy since it is teratogenic and embryotoxic when used in pregnant rats [165] .
Ascaris lumbricoides occasionally causes severe disease, particularly during larval migration to extraintestinal sites. Treatment during pregnancy should be limited to cases of heavy infestation or symptomatic disease [160] . The treatment of choice for intestinal infection is piperazine; no harmful effects on the fetus have been reported following maternal administration of this drug [116, 164] .
Strongyloidiasis carries a serious potential risk and should always be treated, even when asymptomatic. If an infection is not treated, cyclic autoinfection may develop, allowing larvae to penetrate the colon or the perianal mucosa, migrate through the systemic circulation, and reenter the intestine. Severe autoinfection can be fatal, especially in patients receiving corticosteroids or other immunosuppressive drugs. Thiabendazole is the treatment of choice for strongyloidiasis. It is well absorbed after oral administration, and most of the drug is metabolized and excreted in the urine within 24 hr [164] . The safety of thiabendazole during pregnancy and breast-feeding, however, has not been established.
(2) Cestodes (tapeworms). Cestodiasis during pregnancy causes no serious complications; maternal disease is of concern only when cysticercosis develops following infestation by Taenia solium. Niclosamide is the preferred agent for the treatment of infections with the beef, pork, and fish tapeworms (i.e., Taenia saginata, T solium, and Diphyllobothrium latum). Niclosamide is not absorbed after oral administration, and no serious adverse reactions have been reported [164] . Since tapeworm infections generally are not life-threatening, however, it is recommended that treatment of pregnant women be postponed until after delivery. Cysticercosis due to T solium larvae is best treated by surgical resection. Praziquantel, a new anticestodal drug, appears promising, particularly in neurocysticercosis. The drug is absorbed rapidly, distributed throughout all tissues, metabolized completely, and excreted readily [141] . It is not known to have any teratogenic, embryotoxic, or mutagenic effects [141] .
Summary and Conclusions
In this review we have examined the pharmacokinetic and therapeutic implications of antimicrobial therapy during pregnancy. While the need to evaluate critically the safety and potential teratogenicity of all therapeutic agents administered during pregnancy has been emphasized, the information currently available to assure the optimal usage of these drugs during the antenatal period is sparse. Precise pharmacokinetic data, particularly on the newer antifungal, antiviral, and antiparasitic agents, are lacking. While it is clear that all antimicrobial agents are potentially harmful to the fetus and that their administration during pregnancy must be limited to specific indications in both the mother and the fetus, a greater understanding of the nature and consequences of various infectious processes during pregnancy is needed. The potential risks and benefits of antimicrobial therapy must be assessed individually on the basis of relevant clinical and pharmacologic data that are appropriate to the specific clinical setting of both mother and fetus. Only in this manner can a more effective approach to antimicrobial therapy be developed for the pregnant patient. exposure histories during pregnancy. Am J Obstet Gy
